Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Replimune Group, Inc. (REPL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
08/03/2023 8-K Quarterly results
Docs: "Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update",
"Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB099280 in Patients with Cutaneous Squamous Cell Carcinoma"
07/20/2023 8-K Quarterly results
05/18/2023 8-K Quarterly results
Docs: "Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update"
02/27/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
02/09/2023 8-K Quarterly results
Docs: "Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update"
01/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer Woburn, MA, January 4, 2023 – Replimune Group, Inc. , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies , announced today the appointment of Christopher Sarchi as Replimune’ s Chief Commercial Officer and the appointment of Sushil Patel, Ph.D., previously Replimune’ s Chief Commercial Officer, to a newly formed position of Chief Strategy Officer, effective immediately. “These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 launch of RP1,” said Philip Astley-Sparke, Chie..."
12/12/2022 8-K Quarterly results
12/07/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/07/2022 8-K Quarterly results
09/08/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/04/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
03/30/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies"
02/03/2022 8-K Quarterly results
01/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors Woburn, MA, January 31, 2022 – Replimune Group Inc. , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Otello Stampacchia, Ph.D., of Omega Funds, has resigned from the company’s Board of Directors. Dr. Stampacchia joined the Replimune Board in 2015, concurrent with Omega co-leading Replimune’s seed financing. Dr. Stampacchia has resigned to focus his efforts on his growing commitments at Omega and its many portfolio companies. “I would personally like to thank Otello for his numerous contributions to Replimune’s Board of Directors as we have grown from concept to a late-stage development company” said Philip A..."
01/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones"
12/02/2021 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update"
09/09/2021 8-K Quarterly results
08/25/2021 8-K Quarterly results
08/06/2021 8-K Quarterly results
Docs: "Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update"
06/03/2021 8-K Quarterly results
05/20/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/21/2021 8-K Quarterly results
04/12/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/21/2020 8-K Termination of a Material Definitive Agreement
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy